O Shaughnessy Asset Management LLC Takes Position in USANA Health Sciences, Inc. (USNA)

O Shaughnessy Asset Management LLC acquired a new stake in USANA Health Sciences, Inc. (NYSE:USNA) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 2,089 shares of the company’s stock, valued at approximately $179,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Aperio Group LLC increased its stake in shares of USANA Health Sciences by 12.3% during the first quarter. Aperio Group LLC now owns 25,329 shares of the company’s stock worth $2,176,000 after acquiring an additional 2,780 shares during the period. Schwab Charles Investment Management Inc. increased its stake in shares of USANA Health Sciences by 53.6% during the first quarter. Schwab Charles Investment Management Inc. now owns 128,191 shares of the company’s stock worth $11,012,000 after acquiring an additional 44,707 shares during the period. Chicago Equity Partners LLC increased its stake in shares of USANA Health Sciences by 4.7% during the first quarter. Chicago Equity Partners LLC now owns 12,885 shares of the company’s stock worth $1,107,000 after acquiring an additional 580 shares during the period. Hood River Capital Management LLC acquired a new position in shares of USANA Health Sciences during the first quarter worth about $13,116,000. Finally, Robeco Institutional Asset Management B.V. increased its stake in shares of USANA Health Sciences by 18.3% during the first quarter. Robeco Institutional Asset Management B.V. now owns 21,561 shares of the company’s stock worth $1,851,000 after acquiring an additional 3,331 shares during the period. Institutional investors own 48.85% of the company’s stock.

In related news, insider David Mulham Mulham sold 14,733 shares of the business’s stock in a transaction dated Wednesday, May 16th. The shares were sold at an average price of $113.03, for a total transaction of $1,665,270.99. Following the sale, the insider now owns 14,733 shares of the company’s stock, valued at $1,665,270.99. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Myron W. Wentz sold 228,000 shares of the business’s stock in a transaction dated Monday, March 12th. The stock was sold at an average price of $81.10, for a total transaction of $18,490,800.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 604,362 shares of company stock worth $50,493,263. 48.00% of the stock is owned by insiders.

A number of research analysts have recently issued reports on USNA shares. Sidoti lowered shares of USANA Health Sciences from a “buy” rating to a “neutral” rating in a research note on Wednesday, January 24th. Pivotal Research boosted their price target on shares of USANA Health Sciences from $80.00 to $95.00 and gave the stock a “buy” rating in a research note on Wednesday, February 7th. TheStreet lowered shares of USANA Health Sciences from a “b+” rating to a “c+” rating in a research note on Tuesday, February 6th. Finally, ValuEngine upgraded shares of USANA Health Sciences from a “hold” rating to a “buy” rating in a research note on Wednesday, May 2nd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $95.00.

USNA stock opened at $118.90 on Tuesday. The stock has a market cap of $2.86 billion, a P/E ratio of 29.29 and a beta of 0.76. USANA Health Sciences, Inc. has a 52 week low of $52.80 and a 52 week high of $120.10.

USANA Health Sciences (NYSE:USNA) last released its quarterly earnings data on Tuesday, April 24th. The company reported $1.19 EPS for the quarter, topping analysts’ consensus estimates of $1.05 by $0.14. The firm had revenue of $292.00 million for the quarter, compared to the consensus estimate of $268.93 million. USANA Health Sciences had a net margin of 6.47% and a return on equity of 27.92%. The firm’s revenue was up 14.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.91 earnings per share. analysts forecast that USANA Health Sciences, Inc. will post 4.4 EPS for the current year.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition.

Institutional Ownership by Quarter for USANA Health Sciences (NYSE:USNA)

Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply